Literature DB >> 6981575

The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study.

D Lebrec, P Hillon, C Muńoz, G Goldfarb, O Nouel, J P Benhamou.   

Abstract

The gradient between wedged and free hepatic venous pressures was measured in patients with alcoholic cirrhosis before and 1, 3, and 9 months after continuous oral administration of propranolol at doses reducing the heart rate by 25% or after administration of a placebo. The gradient between wedged and free hepatic venous pressures decreased throughout the duration of propranolol administration, and it did not significantly change in the patients receiving placebo. Since the gradient between wedged and free hepatic venous pressures closely reflects portal venous pressure in alcoholic cirrhosis, it is concluded that continuous oral administration of propranolol produced sustained reduction in portal venous pressure in these patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981575     DOI: 10.1002/hep.1840020502

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

2.  Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis.

Authors:  S Sugano; T Kawafune; T Okajima; K Ishii; M Watanabe; N Takamura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 3.  Drugs used in therapy of portal hypertension.

Authors:  Dhiraj Tripathi
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

4.  Hemodynamic effect of propranolol on portal hypertension in patients with HBsAg-positive cirrhosis.

Authors:  C W Kong; C S Lay; Y T Tsai; S D Lee; K H Lai; K J Lo; B N Chiang
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199

5.  Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis.

Authors:  A Braillon; P Cales; D Valla; D Gaudy; P Geoffroy; D Lebrec
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

6.  Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension.

Authors:  D Bihari; D Westaby; A Gimson; I Crossley; J Harry; R Williams
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

Review 7.  The medical prevention of variceal bleeding.

Authors:  D Lebrec
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

8.  Postprandial vascular response in patients with cirrhosis. Short-term effects of propranolol administration.

Authors:  D Alvarez; C Miguez; A Podesta; R Terg; A Sanchez Malo; J C Bandi; S Sanchez; R Mastai
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

9.  Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.

Authors:  C Merkel; D Sacerdoti; G F Finucci; R Zuin; G Bazzerla; M Bolognesi; A Gatta
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

10.  Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis.

Authors:  T Sauerbruch; G Kleber; A Gerbes; G Paumgartner
Journal:  Klin Wochenschr       Date:  1986-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.